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Abstract:
Objectives 
HTA can impact health inequities through its role in accessing health 
technologies and interventions. This paper presents a novel checklist to 
guide HTA practitioners looking to include equity considerations in their 
work: the equity checklist for HTA (ECHTA). The list is pragmatically 
organised according to the generic HTA phases and can be consulted at 
each step. 
Methods 
A first set of items was based on the framework for equity in HTA 
developed by Culyer & Bombard. After they were reworded and 
organised according to five HTA phases, they were complemented by 
elements emerging from a literature search. Consultations with method 
experts, decision-makers, and stakeholders further refined the items. 
Further feedback was sought during a presentation of the tool at an 
international HTA conference. Lastly, the checklist was piloted through 
an HTA. 
Results 
The equity checklist for HTA proposes elements to be considered at each 
one of the five HTA phases: Scoping, Evaluation, Recommendations and 
Conclusions, Knowledge Translation and Implementation, and 
Reassessment. More than a simple checklist, the tool provides details 
and examples which guide the evaluators through the analysis at each 
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phase. A pilot test is also presented, which demonstrates ECHTA’s 
usability and added-value. 
Conclusions 
ECHTA provides guidance for HTA evaluators wishing to ensure their 
conclusions do not contribute to inequalities in health. Several points to 
build upon the current checklist will be addressed by a working group of 
experts and further feedback is welcome from evaluators having used 
the tool. 
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HTA can impact health inequities by informing health care priority setting decisions. This 
paper presents a novel checklist to guide HTA practitioners looking to include equity 
considerations in their work: the equity checklist for HTA (ECHTA). The list is 
pragmatically organised according to the generic HTA phases and can be consulted at 
each step. 
Methods
A first set of items was based on the framework for equity in HTA developed by Culyer & 
Bombard. After rewording and re-organising according to five HTA phases, they were 
complemented by elements emerging from a literature search. Consultations with 
method experts, decision-makers, and stakeholders further refined the items. Further 
feedback was sought during a presentation of the tool at an international HTA 
conference. Lastly, the checklist was piloted through all five stages of an HTA. 
Results
The equity checklist for HTA proposes elements to be considered at each one of the five 
HTA phases: Scoping, Evaluation, Recommendations and Conclusions, Knowledge 
Translation and Implementation, and Reassessment. More than a simple checklist, the 
tool provides details and examples which guide the evaluators through the analysis at 
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each phase. A pilot test is also presented, which demonstrates ECHTA’s usability and 
added-value. 
Conclusions
ECHTA provides guidance for HTA evaluators wishing to ensure their conclusions do not 
contribute to inequalities in health. Several points to build upon the current checklist 
will be addressed by a working group of experts and further feedback is welcome from 
evaluators having used the tool. 
Key words: equity, health technology assessment, health disparity 
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Given its influential role in prioritising access to safe and effective health technologies 
and interventions, health technology assessment (HTA) also has the potential to 
influence inequities in health. Along with growing recognition of the need to explicitly 
consider the impact of health decisions on health equity (1), there is impetus to 
undertake  equity analyses within HTAs. However, a number of surveys have found that 
the inclusion of equity considerations and analyses in HTA remains infrequent (2,3). 
Different reasons might explain this; including lack of relevant methodological 
knowledge and training as well as  the greater time and human resource requirements 
and sparse primary data. HTA practitioners aspiring to assess inequities and provide 
recommendations to decrease them might therefore benefit from guidance on how to 
do so. This article describes the development of a checklist which aims to bridge this 
gap: the equity checklist for HTA (ECHTA). 
Defining health inequity 
A widely used definition of health inequity has been proposed by Whitehead (1992) and 
built upon by the WHO’s Commission on Social Determinants of Health (CSDH)(4,5). It 
posits that health inequities are not merely differences in health status (termed 
‟inequalities”) but differences between groups that are unnecessary, avoidable unfair 
and unjust(6). The criteria of fairness and justice can be understood as systematic 
differences considered avoidable (5). Thus, all should have a ‟fair and just opportunity 
to be as healthy as possible”(7). The use of this definition in turn assumes that equity 
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considerations in the context of HTA imply a normative analysis since value judgements 
are applied to enable actions through recommendations, beyond the simple description 
of the current state of affairs. Nonetheless, the operationalisation of this definition 
firstly requires an understanding of the terminology used to refer to the individuals 
suffering from these inequities. Different terms have been proposed and used by 
different individuals and groups to refer to themselves. These include marginalised, 
disadvantaged, individuals living in positions of vulnerability, amongst many others. 
These terms have different implications and the authors recognise the agency of 
individuals in choosing the term that most empowers them (8). For the purposes of this 
paper, the term ‟disadvantaged” will be used; simply to denote that a health inequity 
represents a disadvantage in health status that is unfair. The authors hope, however, 
that these groups will recognise themselves in these writings. 
Operationalising the definition of health equity also calls for an understanding of the 
factors modulating health, including health inequities. The authors adopt the CSDH’s 
perspective and therefore recognise that several aspects influence the health impacts of 
a technology or intervention beyond its efficacy and safety. Notably, economic, 
organisational, sociodemographic, and other contextual elements modulate the 
differential effects of a technology or intervention (5,7,8).  Different mnemonic aids and 
tools have also been developed to guide the recognition of potentially disadvantaged 
groups. For instance, the acronym PROGRESS Plus has been proposed to emphasize that 
inequities in health are not only due to poverty (that is, the rich-poor gap) but also other 
critically important factors, such as: Place of residence, Race/ethnicity/culture/language, 
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Occupation, Gender/sex, Religion, Education, Socio-economic status, Social capital; in 
addition the ‟Plus” refers to any other relevant characteristic such as age, sexual 
orientation, or disability (9). This provides categories through which disparities in health 
and its social determinants can be qualitatively and quantitatively analysed. Groups and 
individuals can, however, belong to more than one of these defined categories that is, 
they find themselves at the intersection of various categories of population groups (10). 
For instance, an individual might be an immigrant transgender woman living in a rural 
area. Intersectionality refers to the unique interplay between different axes which result 
in distinct societal power relations and not simply the sum of the categorical axes to 
which individuals relate (10). 
Applying health inequity concepts to HTA
Such approaches remain however rather descriptive for the purposes of undertaking 
HTA. To address this gap, theoretical guidance has been increasingly provided. One such 
example is the Equity Framework for HTA suggested by Culyer and Bombard (2012). The 
framework is aimed at impacting both the procedures of the HTA endeavour as well as 
the final conclusions and recommendations resulting from the HTA. It consists of 13 
guiding elements to consider during the HTA process (11). Another example is the GPS-
Health tool which provides a concise list of criteria for guiding healthcare priority setting 
in addition to cost-effectiveness evaluation(12). These tools, however, are not 
pragmatic since they are not organised in a manner that allows practitioners to follow 
along each step of an HTA. The challenge therefore becomes to utilise tools that can 
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analyse inequities in health and its determinants at each phase. A number of references 
provide explicit methods or tools to guide the choice of HTA evaluators (13–15).  
The tool presented here did not seek to address the specific methodological approaches 
to be utilised. Rather, it seeks to provide general points of reflection to guide HTA 
practitioners and researchers in their consideration of health equity. Thus, this paper’s 
objective is to propose a checklist that builds on previous work in the field and present 
the initial face and content validation of the work undertaken. Given that the tool is 
based on an array of international tools and frameworks and that it remains generic in 
its approach, our aim is that it can be useful to all HTA practitioners and researchers 
wishing to include equity considerations throughout their undertaking of an assessment. 
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A first set of items was defined based on the thirteen domains outlined by Culyer and 
Bombard(11) in their framework for equity in HTA. The domains are enumerated in 
Figure 1.
These domains, and the concepts they contain, were rephrased to render them more 
pragmatic. To increase user-friendliness, they were then organized into the HTA steps 
inspired by the HTA Iterative Loop suggested by Bennett & Tugwell (16) as well as the 
equity health impact assessment literature (17). This perspective views HTA as an 
iterative cycle which goes beyond evaluating and providing recommendations. Indeed, it 
evolves from scoping through to evaluation, recommendation and conclusion, 
knowledge translation and implementation, and lastly reassessment. 
A non-systematic literature search was undertaken to complement the initial list with 
additional elements and considerations. Methodological guidance tools and documents 
relating to the inclusion of equity in HTA were searched. First, generic searches on 
Google and Google Scholar using a combination of synonyms for the concepts of health 
technology assessment and equity were undertaken. Second, the websites of the 
following organizations were also targeted: HTA International (including the websites of 
their Ethics interest group and their Patients and Citizen Involvement interest group), 
the International Network of Agencies for HTA (INAHTA), Quebec’s National Institute of 
Excellence in Health and Social Services (INESSS), the Canadian Agency for Drugs and 
Technologies in Health, the World Health Organization (WHO), and the Cochrane 
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Collaboration. Select elements were therefore included from seven additional studies 
and guidelines (9,18–23). 
Feedback was sought from experts on equity in HTA through email and telephone 
correspondence. The list of experts was expanded through snowball referencing, for a 
total of 10 experts. The experts represented a wide variety of perspectives emanating 
from different contexts, including academia in high-income and low and middle-income 
countries, governmental agencies as well as HTA practitioners at national and regional 
levels. These experts appear as authors on this paper or are acknowledged, depending 
on their degree of participation and willingness to participate as authors of the work. 
The feedback received was compiled and analysed through a content thematic analysis. 
Themes and codes were created using a general inductive analysis approach (24). 
Themes first depended on whether they pertained to the tool itself or its description 
within this paper. Those themes pertaining to the tool were further categorised 
according to the relevant section of the tool. There were no contradictions or 
incoherence in the comments provided. This allowed for the validation of the checklist 
items as well as their organization and presentation. The tool was also presented at an 
international conference on HTA in 2019 and the additional feedback received verbally 
was incorporated into the checklist (25). 
Since the goal was to develop a guidance checklist, rather than an evaluation tool, 
external validity and interrater reliability were not tested. A pilot test was undertaken 
with an HTA project on corticosteroid injections and other treatments for chronic low 
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back pain in the context of a regional health network in Quebec (26). The project 
manager was the first author on this paper (MB) and the supervisor was another co-
author (PD). The project also involved an advisory committee made up of a wide range 
of stakeholders, including healthcare professionals, managers, and users and parents of 
children users. This committee was involved in all phases of the HTA. It was informed 
and invited to further comment and discuss on the analyses, proposed changes, and 
provide data that might answer those equity-related questions. The elements of the 
checklist were consulted at each separate phase of the HTA project. Adjustments were 
made when the analysis of a checklist element brought up concerns that had previously 
not been considered. As a result, the checklist was subsequently further revised so as to 
facilitate its use. 
RESULTS 
The result was a five-phase checklist, containing explanations and examples, aimed at 
HTA evaluators to facilitate the consideration of various domains of health equity within 
the evaluation process: the Equity checklist for health technology assessment (ECHTA). 
Once a decision has been made to appraise a particular technology or intervention, 
ECHTA can accompany evaluators through all five phases of an HTA. They include the 
initial negotiations with decision-makers requesting the evaluation and defining the 
scope of the HTA, through to the evaluation, and the development of recommendations 
and lastly, knowledge translation and implementation strategies that consider 
disadvantaged population groups as well as understanding the need to reassess the 
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technology or intervention. Although all five phases may not take place in every HTA, 
evaluators may refer to the items in the phases relevant to their particular project. It is 
important to note that, the checklist is not meant to be completed in one sitting. Rather, 
it can be consulted at the start of each phase and in an iterative manner throughout the 
completion of the work. 
The first phase, Scoping Phase, brings questions relative to defining, identifying, and 
contextualizing equity, such as identifying potential disadvantaged groups and including 
vulnerability factors in a logic model or other theoretical frameworks. Second, the 
Evaluation Phase facilitates the adoption of methodological approaches which are 
conducive to analysing inequities as well as considering contextual realities which have 
an impact on inequities. Its elements are subdivided into four categories: outcome 
measures, data collection and analysis, contextual considerations, and stakeholder 
involvement. Third, the Recommendations and Conclusions Phase addresses evidence 
synthesis approaches, the contextual factors to consid r, as well as the generalisability 
versus specificity of recommendations to particular population groups. This aims at 
ensuring that the drafted recommendations consider existing inequities. It is also 
imperative that they avoid contributing to greater inequities. The elements of this phase 
are categorised according to scope, contextual considerations, and stakeholder 
involvement. Fourth, the Knowledge Translation and Implementation Phase prompts 
evaluators to consider whether the chosen implementation methods favour certain 
population groups as well as whether there might be a benefit to targeted knowledge 
translation approaches. Lastly, the fifth Reassessment Phase questions the 
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methodological approaches as well as any changes in context that might have occurred 
since the initial evaluation. The full list of ECHTA elements is found in table 1. 
Using ECHTA
As previously mentioned, ECHTA could be used by any researchers or evaluators wishing 
to consider health inequities in their HTA. The checklist acts as a prompt for the various 
elements to consider during the undertaking of an HTA. It is not meant to be completed 
in one sitting, but rather to be consulted at beginning of each step. Indeed, although the 
list may seem long and time-consuming, it could instead be regarded as five 
interconnected lists. Certain elements may not be relevant to the HTA at hand and 
therefore may be omitted. Their relevance, however, can only be determined upon 
adequate consideration. The authors nevertheless recommend that evaluators become 
familiar with the entirety of the checklist on the first use. The use of ECHTA may 
certainly be easier for evaluators with prior knowledge of ethics and equity evaluations. 
The checklist remains nonetheless aimed at all HTA evaluators with the hopes that it will 
increase knowledge of these issues. 
Stakeholder involvement 
Stakeholders can be defined as any ‟individual with an interest in the outcome of the 
HTA process final decision” (27). They may include healthcare professionals, health 
system payers, managers and other employees, patients, users, and carers. The level of 
involvement stakeholders can have within an HTA may vary according to the length and 
depth of the assessment or according to the perceived purpose of stakeholders that 
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HTA evaluators may have. Stakeholders may only be included as a source of data or on a 
sporadic basis throughout the project or they may be involved throughout the entire 
process. Stakeholders may also be formally included in the process via participation in 
an advisory committee, which has a say in every phase of the HTA, including the co-
construction of final recommendations and conclusions (27).  While adopting an equity 
lens, the advisory committee should be cognisant of representing a diversity of relevant 
population groups. Indeed, it is important to note that the involvement of stakeholders 
does not inherently result in an understanding of health inequity concerns. Rather, it is 
advisable to ensure that the stakeholders, including patients and citizens, involved 
represent various population groups, notably disadvantaged groups. A limitation of 
stakeholder involvement in HTA relates with the overrepresentation of certain interests and 
views to the detriment of other relevant social elements. This drawback is not specific to equity 
analyses but could be relevant to any social value judgment. This concern can be mitigated by a 
transparent and accountable process including the disclosure of conflicts of interests of all 
stakeholders included.
Pilot test 
To assess the usability of the checklist, a pilot test was undertaken through a 
comprehensive HTA on corticosteroid injections and other treatments for chronic low 
back pain. The HTA aimed at answering the needs of a regional health network in the 
province of Quebec, Canada. As such, the HTA assessed the safety and efficacy of 
corticosteroid injections, guidelines for the other treatments, as well as organisational 
considerations for the optimal use of recommended treatments. The use of ECHTA 
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rendered explicit the consideration of various factors modulating equity, beyond the 
differential efficacy of at risk groups. For instance, it prompted the definition of what 
constitutes inequities in the context of the region and consequently enabled the team 
to engage with the appropriate stakeholders to further understand these realities. 
During the evaluation phase, ECHTA pushed the evaluators to consider inequity in the 
choice of outcome measures and to seek contextual data that also considered minority 
groups in the population. These considerations resulted in recommendations that 
explicitly took into account the potential realities of these groups. Table 2 presents 
examples of these recommendations, which are contrasted with possible outcomes had 
ECHTA not been used. These possible outcomes are inferred from the conclusions 
usually obtained in previous HTA’s undertaken by our unit that did not undertake an 
equity analysis.  
ECHTA has yet to be used in the fourth Knowledge Translation and Implementation 
phase or the fifth Reassessment Phase of an HTA. This, combined with the fact that 
these phases are seldom described in HTA reports, has meant that a relatively smaller 
number of equity elements of consideration are currently listed under these phases. It is 
the hope of the authors that these phases will be further populated as the tool is 
utilised and feedback is provided from the HTA community. 
DISCUSSION 
This paper presents a first iteration of ECHTA, a checklist to guide the consideration of 
equity during the undertaking of an HTA and the results of its first application. This 
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checklist does not claim to answer all barriers impeding the greater prevalence of equity 
analyses in HTA. Rather, it is aimed at practitioners already considering including an 
equity analysis in their work. It is meant as a starting point to reflect on the factors 
potentially impacting inequities and the means to consider them throughout the HTA. 
To the authors’ knowledge, this is the first pragmatic checklist that can be used as a 
reference throughout all the phases of an HTA. It does, however, base itself on the rich 
pre-existing work in the field (11,16,18,21). 
The tool is meant for all HTA evaluators, regardless of their expertise in health equity 
analysis. Although evaluators with less experience doing equity or ethics analyses might 
encounter a greater learning curve and might require consulting additional references. 
It is our hope that ECHTA will come as a facilitator to their learning. Furthermore, the 
use of ECHTA certainly generates the need for greater resources. For instance, the 
process of collecting and analysing disaggregated data, which adequately represents 
various minority groups can be more difficult and lengthy. Additionally, discussions with 
stakeholders and committees may be longer given the greater data, and sometimes 
controversial, nature of recommendations that require further analyses of the 
healthcare system’s value judgements. The precise amount of additional resources 
required is largely dependent on the project, its research questions, and the context 
within which the analysis is made. Nevertheless, much like other methodological 
developments in HTA, we view equity analyses in HTA as strengthening the decision-
making process and contributing to its legitimacy. A first pilot has demonstrated its 
usability and added-value. It has shown that the use of ECHTA can aid in the 
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consideration of the impact on different population groups and result in 
recommendations which take these groups into account. Thus, these recommendations 
can have concrete impacts on these population groups and ensure that the results of 
the HTA do not exacerbate inequities and, ideally, contribute to diminishing them. 
The subsequent use of ECHTA in various types of HTAs will further strengthen the 
checklist through future revisions, notably through additional elements in the fourth 
Knowledge Translation and Implementation phase and the fifth Reassessment Phase. 
Indeed, these latter phases are often influenced by a greater number of factors and 
actors that go beyond the core HTA evaluation team and might therefore require more 
nuanced considerations. Similarly, the prioritisation of the HTAs to be undertaken may 
involve various actors beyond the evaluation team and the selection criteria might not 
always include health inequities. Such processes can subsequently lead to a systematic 
omission of the needs of minority groups. This important element is currently missing 
from ECHTA. HTA evaluators should remain cognisant of such prioritisation criteria and 
be reflexive and explicit of it in their identification of opportunity costs in the scoping 
phase. Although the inclusion of knowledge translation experts, decision-makers, and 
healthcare users representing those disadvantaged groups throughout the entire HTA 
process can help remedy this situation, it is important to acknowledge that the 
responsibility frequently lies beyond that of the HTA evaluation team. Nevertheless, the 
authors aspire to provide more detailed guidance on this concern in future work. 
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Other developments for ECHTA might include more specific guidance on addressing 
intersectionality considerations as well as a shorter version of the checklist that 
identifies those considerations that are usually of importance for policy makers or for 
which there is often evidence.  An international group of experts has formed a 
workgroup to further the development of the tool in order to address these points and 
others that might arise. The current iteration is ready to be used and the authors 
welcome any constructive feedback resulting from its use in other HTAs. Amongst other 
things, the checklist would benefit from use in HTAs in different settings, including 
resource-poor settings and examples outside of North America. The authors realise that 
a number of terms and concepts introduced in ECHTA are specific to the health equity 
literature and might benefit from further explanation. 
The length of ECHTA might lead to think that its main use would be for comprehensive 
HTAs. These HTAs, having longer timelines and greater resources, would have a greater 
capacity for additional analyses. Evaluators are nevertheless invited to use ECHTA for all 
their evaluations. Indeed, recommendations and conclusions emanating from rapid 
HTAs have the same potential of differentially impacting minority groups as more 
comprehensive evaluations. Several strategies could be adopted when using ECHTA for 
shorter HTAs. For instance, checklist items could be considered but analysed in lesser 
depth. In addition, certain inequities emerging during the first Scoping Phase could be 
prioritised according to their severity or the capacity to address them given limited 
resources. Such normative value judgements should be undertaken in consultation with 
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decision-makers and stakeholders. Additionally, the limitations of these simplified 
analyses must be addressed. These could give rise to specific guidance for rapid HTAs. 
Despite these shortcomings, ECHTA aims to facilitate the consideration of health 
inequity during the HTA process and presents a pragmatic approach to achieve this. The 
authors hope that the usefulness of ECHTA will be recognized and improved as is it used 
and that HTA evaluators can look to these working examples for inspiration.  We also 
hope this work will catalyze further engagement and discussion to better understand 
the barriers that have prevented equity analyses in HTA from being more prevalent. 
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Table 1 Equity Checklist for HTA (ECHTA)
Scoping phase 
Category Key question Details 
 Define: equity of what?  Dimensions of equity: Need, 
access, health status, 
function, prognostic with or 
without the intervention, 
quality of life, social 
determinants of health, etc.
 Explore current inequalities 
related to the HTA during 
the exploratory review. 
 Define what would 
constitute an unjust state of 
affairs or situation regarding 
the inequalities found. 
 Equity goals: (i) equal 
access, (ii) equal utilisation, 




 Define population subgroups 
to consider through the use 
of a logic model and/or 
theoretical basis. 
 Are we interested in 
inequality in health 
between social groups? 
(e.g. using the PROGRESS+ 
or other relevant acronyms) 
 Are we interested in 
inequality in health 
between disease groups? 
 Are we interested in 
inequality between future 
health or lifetime health?
 Is a specific subgroup 
benefitting from this 
technology?
 How is inequity linked to 
inputs, process, and outputs 
of health and social 
services?
 How does one account for 
disadvantages?
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 Could the scope of the HTA 
lead to potential biases for or 
against specific population 
groups?
 This can include the 
research questions or 
breadth and depth of the 
analysis. 
 What are the opportunity 
costs of conducting an HTA of 
one intervention/technology 
over another?
 How will the 
intervention/technology be 
funded and what would be 
the distribution of the 
opportunity cost?
 The cost of undertaking this 
HTA over another more 
relevant to a disadvantaged 
group.
 The costs that might 
negatively impact specific 
disadvantaged groups. 
 How will the funding source 
for this intervention impact 
other existing healthcare 
programs (e.g. taxation, 
cuts to other programs, 
public versus private funds, 
etc.)




 Are there implicit or indirect 




 Are there historical 
disadvantages to consider 
that might impact the choice 
of variables to assess, the 
choice of methods, etc.? 
 For example: indigenous 
populations, racialized 
groups
 Were all relevant 
stakeholders included in the 
scoping process?
 Does the inclusion of 
different stakeholders 
impact/change the process?
 Examples: healthcare 
professionals, 
patients/system users, 
managers, and members of 
the public
 Does the way in which 
stakeholders are involved 
impede certain population 




 Which are the most 
appropriate ways of including 
patient perspectives?
 How to consider the 
diversity of patients? 
 Is there an institutional 
policy on the inclusion of 
patients?
Evaluation phase 
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Category Key question Details 
 Are the outcome measures 
chosen relevant to patients’ 
perspectives?
 Is there a study referenced 
demonstrating the 
importance of these 
outcomes to patients?
 Were patients/system users 
involved in the choice of 
outcome measures?
 Do outcome measures 
include the different aspects 
through which inequities can 
emerge?
 Aspects of outcome 
measures: coverage, 
prevalence, uptake, access 
to care, etc.
 Is it possible to assess 
baseline inequalities 
through quantitative and 
qualitative data?
 Do defined outcome 
measures omit important 
dimensions that may 
exclude certain population 
groups? 
 Are the thresholds used to 
define improvements or 
deteriorations in outcome 
measures appropriate for all 
population groups?  
 Thresholds might be 




 Is there an economic analysis 
and does it include an equity 
analysis?
 For example: Distributional 
cost-effectiveness analysis, 
extended cost-effectiveness 
analysis or other forms 
(subgroup analysis, utility 
weights, mathematical 
programming, etc.)
 Are the methods used to 
collect and/or identify data 
conducive to finding data on 
disadvantaged population 
groups? 
 Are disadvantaged groups 
explicitly included in the 
search strategy? 
 Does the grey literature 





 Are analytical methods 
appropriate for all groups? 
 For example: culturally 
acceptable, allow for fair 
representation, etc.
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 Do the tools used to assess 
the evidence incorporate the 
consideration of equity 
elements? 
 The evidence includes 
clinical, economic, 
experiential, etc. 
 Examples of tools: GRADE 
equity, AMSTAR 2, 
distributional CEA, etc.
 Does the analysis of potential 
inequities consider 
cumulative life experiences of 
those impacted?
 Health inequities are 
impacted by a range of 
different disadvantages in a 
person’s life. 
 Are there any institutional 
biases that might contribute 
to inequalities? 
 Are there structural or 
organizational realities that 
disadvantage certain 
groups? 




professionals, etc.) such 
that power dynamics are 
imbalanced? 
 Are there care processes that 
might contribute to 
discrimination? 
 For example: is there a bias 
that favours individuals with 
greater capacity to navigate 
bureaucratic systems; can 
certain care processes 
disadvantage certain 
individuals?
 Do certain special claims have 
to be considered in the 
contextual analysis? 
 For example: need (low 
baseline health status), 
historical claims, willingness 
to pay, etc.
 Are there psychosocial issues 
relevant to your context that 
impact specific population 
groups? 
 These can include various 
social determinants such as 
education, socioeconomic 
status, ethnic and racialized 




 Does the distribution and 
supply of services in your 
context impact inequities in 
health outcomes?
 Distribution disparities can 
be geographic, through 
payment, etc. 
Stakeholder  Are the methods used to  Are there specific tools that 
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include patient perspectives 
appropriate and do not lead 
to a systematic exclusion or 
under-representation of 
certain population groups? 
support the analysis of 
disaggregated data and/or 




 Do the methods used to 
involve stakeholders allow 
for all relevant parties to be 
represented?
 Are there barriers to 
participation not accounted 
for? For example: no public 
transit available, times of 
meeting, etc. 
Recommendations and conclusions phase 
Category Key question Details 
 Were the results synthesized 
using a summary table which 
included findings relating to 
inequity? 
 Summarised results can still 
include findings on 
disadvantaged groups. 
 Do the recommendations 
account for the different 
aspects through which 
inequities can emerge?
 For example: coverage, 
prevalence, uptake, access 
to care, etc.
 Are recommendations 
generalizable to all 
population groups?
 Should some 
recommendations specify 
that they do not apply to 
certain disadvantaged 
groups? 




 Could certain 
recommendations increase 
inequities? 
 Could certain 
recommendations heighten 
the barrier to access to 
healthcare services for 
particular population 
groups? 
 Might certain population 
groups have reduced 
resources as a result of the 
recommendations?  




 Are there legal contexts to 
consider in the 
recommendations? 
 Are there legal aspects 
regarding certain 
population groups that 
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must be taken into account?
 Are there historical 
disadvantages to be 
considered in the 
recommendations?
 For example, specific to 
indigenous groups or 
racialized populations. 
 Are there recommendations 
relating to a change in culture 
and/or the institutional 
system which could 
contribute to inequities? 




 Were all relevant 
stakeholders included in the 
scoping process?
 Do the methods used to 
involve stakeholders allow for 
all relevant parties to be 
represented?
 Does the way in which 
stakeholders are involved 
impede certain population 
groups from being 
adequately represented? 
For example: the methods 
for deliberation create 
barriers for participation of 
certain persons, capacity for 
transportation, level of 
literacy for understanding 
the final written product, 
etc.
Knowledge translation and implementation phase 
Category Key question Details 
 Do the approaches selected 
to implement 
recommendations favour 
certain population groups 
above others?
 Selected implementation 
methods may not be 
suitable or optimal for 
certain disadvantaged 
groups. For example: 
reading material may 
exclude groups with lower 
literacy. 
 Does the prioritisation of 
recommendations to be 
implemented favour certain 
population groups above 
others?







 Do certain population groups 
within each stakeholder 
category require targeted 
knowledge translation 
 Might separate and specific 
approaches be beneficial to 
enhance the reach to 
certain population groups?
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Category Key question Details 
Methods  Does the methodological 
approach chosen allow for 
the analysis of disaggregated 
data by relevant population 
groups? 
 Is it possible to assess the 
difference in inequalities 
from baseline through 




 Were certain population 
groups not considered in 
previous HTA phases 
impacted differently? 
 Were there contextual 
changes that might impact 
HTA outcomes with regards 
to different population 
groups? 
 Were there disadvantaged 
groups that were omitted in 
the previous assessment?
 Are there new populations 
groups to consider? 
Table 2 Examples of impacts on recommendations through the use of ECHTA
Recommendations using ECHTA Possible outcome without ECHTA
Caution should be taken when prescribing 
corticosteroid injections to patients at 
greater risk, such as patients over 50 years 
of age. 
Consideration of average efficacy with 
little consideration of distribution across 
at risk population groups. 
Evaluate the need for additional 
fluoroscopic equipment throughout the 
region (notably in areas further from the 
largest urban centre). 
Little consideration of barriers resulting 
from geographic distribution of services 
throughout the large territory of the 
region. 
Patient preferences, notably treatments 
other than injections, are imbedded in the 
final recommendations. 
No explicit assessment of local patient 
preferences and only safety and efficacy 
influence the recommendations. 
Ensure adequate public access to 
physiotherapy and psychotherapy. 
No consideration of socioeconomic 
disparity in access to interdisciplinary 
treatment due to insufficient public 
services in physiotherapy and 
psychotherapy. 
Further evaluate accessibility challenges 
for English-speaking and other linguistic 
minorities. 
No consideration of local linguistic 
minorities. 
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Figure 1 : Culyer and Bombard framework for equity in HTA domains 
Culyer and Bombard framework for equity in HTA domains 
1- Reviewing the distinction between equity and equality and the dimensions these are 
reacting to; 
2- Adequacy of the domains of equity; such as direct or indirect consequences, disease 
focus versus other characteristics, health care inputs-processes-outcomes, etc.; 
3- Legal obligations; such as antidiscrimination legislation; 
4- Embedded inequities; which arise from the characteristics of the HTA analyses or the 
intervention being assessed; 
5- Institutional bias; which leads to inequities imbedded within organizations; 
6- Implicit stereotyping; which refers to assumptions made about a condition or a group 
of people; 
7- Contexts, behaviours, and circumstances; 
8- Processes in HTA; 
9- Hidden opportunity costs; which are costs felt by both those affected by the 
intervention and those impacted by consequential changes in resource distribution; 
10- Processes in the delivery of care; 
11- Special claims; which include claims of need, of responsibility, of historical 
considerations, etc.; 
12- Cumulative effects from past disadvantages or advantages contributing to current 
inequities; 
13- General principles; which refer to the minimal requirements for equity and their 
applicability to the context at hand (11).
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